Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

LONDON, Nov 7 — Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...

Novo Nordisk has announced that its experimental obesity drug, CagriSema, is showing side effects similar to existing GLP-1 drugs. The company expects the new drug to deliver a 25% weight loss. Novo ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Judicial appointments and more - A Trump administration could also seek to undo the stringent patient privacy protections put ...

WASHINGTON: Donald Trump has already appointed three Supreme Court justices. In his second term, he could well have a chance to name two more, creating a high court with a Trump-appointed majority ...